FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201783003> ?p ?o ?g. }

• W3201783003 endingPage "244" @default.
• W3201783003 startingPage "230" @default.
• W3201783003 abstract "We conducted a randomized, placebo-controlled, double-blind study of pediatric lung transplant recipients, hypothesizing that rituximab plus rabbit anti-thymocyte globulin induction would reduce de novo donor-specific human leukocyte antigen antibodies (DSA) development and improve outcomes. We serially obtained clinical data, blood, and respiratory samples for at least one year posttransplant. We analyzed peripheral blood lymphocytes by flow cytometry, serum for antibody development, and respiratory samples for viral infections using multiplex PCR. Of 45 subjects enrolled, 34 were transplanted and 27 randomized to rituximab (n = 15) or placebo (n = 12). No rituximab-treated subjects versus five placebo-treated subjects developed de novo DSA with mean fluorescence intensity >2000. There was no difference between treatment groups in time to the primary composite outcome endpoint (death, bronchiolitis obliterans syndrome [BOS] grade 0-p, obliterative bronchiolitis or listing for retransplant). A post-hoc analysis substituting more stringent chronic lung allograft dysfunction criteria for BOS 0-p showed no difference in outcome (p = .118). The incidence of adverse events including infection and rejection episodes was no different between treatment groups. Although the study was underpowered, we conclude that rituximab induction may have prevented early DSA development in pediatric lung transplant recipients without adverse effects and may improve outcomes (Clinical Trials: NCT02266888). We conducted a randomized, placebo-controlled, double-blind study of pediatric lung transplant recipients, hypothesizing that rituximab plus rabbit anti-thymocyte globulin induction would reduce de novo donor-specific human leukocyte antigen antibodies (DSA) development and improve outcomes. We serially obtained clinical data, blood, and respiratory samples for at least one year posttransplant. We analyzed peripheral blood lymphocytes by flow cytometry, serum for antibody development, and respiratory samples for viral infections using multiplex PCR. Of 45 subjects enrolled, 34 were transplanted and 27 randomized to rituximab (n = 15) or placebo (n = 12). No rituximab-treated subjects versus five placebo-treated subjects developed de novo DSA with mean fluorescence intensity >2000. There was no difference between treatment groups in time to the primary composite outcome endpoint (death, bronchiolitis obliterans syndrome [BOS] grade 0-p, obliterative bronchiolitis or listing for retransplant). A post-hoc analysis substituting more stringent chronic lung allograft dysfunction criteria for BOS 0-p showed no difference in outcome (p = .118). The incidence of adverse events including infection and rejection episodes was no different between treatment groups. Although the study was underpowered, we conclude that rituximab induction may have prevented early DSA development in pediatric lung transplant recipients without adverse effects and may improve outcomes (Clinical Trials: NCT02266888)." @default.
• W3201783003 created "2021-10-11" @default.
• W3201783003 creator A5000869824 @default.
• W3201783003 creator A5000948052 @default.
• W3201783003 creator A5003827669 @default.
• W3201783003 creator A5005697326 @default.
• W3201783003 creator A5008281691 @default.
• W3201783003 creator A5008876887 @default.
• W3201783003 creator A5011158103 @default.
• W3201783003 creator A5023146118 @default.
• W3201783003 creator A5035493599 @default.
• W3201783003 creator A5044240498 @default.
• W3201783003 creator A5054449581 @default.
• W3201783003 creator A5054474365 @default.
• W3201783003 creator A5064875263 @default.
• W3201783003 creator A5067699361 @default.
• W3201783003 creator A5075604584 @default.
• W3201783003 creator A5077564846 @default.
• W3201783003 creator A5085137623 @default.
• W3201783003 creator A5088980123 @default.
• W3201783003 date "2022-01-01" @default.
• W3201783003 modified "2023-10-05" @default.
• W3201783003 title "CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients" @default.
• W3201783003 cites W1513415343 @default.
• W3201783003 cites W1522262223 @default.
• W3201783003 cites W1527068405 @default.
• W3201783003 cites W1527097930 @default.
• W3201783003 cites W1646078758 @default.
• W3201783003 cites W1951218190 @default.
• W3201783003 cites W1976672420 @default.
• W3201783003 cites W2000549992 @default.
• W3201783003 cites W2008744563 @default.
• W3201783003 cites W2018535440 @default.
• W3201783003 cites W2019177796 @default.
• W3201783003 cites W2023720635 @default.
• W3201783003 cites W2034383024 @default.
• W3201783003 cites W2040929409 @default.
• W3201783003 cites W2045177413 @default.
• W3201783003 cites W2049558499 @default.
• W3201783003 cites W2085027215 @default.
• W3201783003 cites W2099785704 @default.
• W3201783003 cites W2105949004 @default.
• W3201783003 cites W2112408403 @default.
• W3201783003 cites W2126010472 @default.
• W3201783003 cites W2126834483 @default.
• W3201783003 cites W2132227824 @default.
• W3201783003 cites W2143015939 @default.
• W3201783003 cites W2146407494 @default.
• W3201783003 cites W2148675722 @default.
• W3201783003 cites W2163013872 @default.
• W3201783003 cites W2328820789 @default.
• W3201783003 cites W2416539102 @default.
• W3201783003 cites W2417155086 @default.
• W3201783003 cites W2418706972 @default.
• W3201783003 cites W2619334489 @default.
• W3201783003 cites W2733868033 @default.
• W3201783003 cites W2769173967 @default.
• W3201783003 cites W2807831050 @default.
• W3201783003 cites W2899153585 @default.
• W3201783003 cites W2933321059 @default.
• W3201783003 cites W2951216667 @default.
• W3201783003 cites W2955740907 @default.
• W3201783003 cites W2967129829 @default.
• W3201783003 cites W2969656576 @default.
• W3201783003 cites W2987823915 @default.
• W3201783003 cites W3084193550 @default.
• W3201783003 cites W4245929611 @default.
• W3201783003 doi "https://doi.org/10.1111/ajt.16862" @default.
• W3201783003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34599540" @default.
• W3201783003 hasPublicationYear "2022" @default.
• W3201783003 type Work @default.
• W3201783003 sameAs 3201783003 @default.
• W3201783003 citedByCount "2" @default.
• W3201783003 countsByYear W32017830032022 @default.
• W3201783003 countsByYear W32017830032023 @default.
• W3201783003 crossrefType "journal-article" @default.
• W3201783003 hasAuthorship W3201783003A5000869824 @default.
• W3201783003 hasAuthorship W3201783003A5000948052 @default.
• W3201783003 hasAuthorship W3201783003A5003827669 @default.
• W3201783003 hasAuthorship W3201783003A5005697326 @default.
• W3201783003 hasAuthorship W3201783003A5008281691 @default.
• W3201783003 hasAuthorship W3201783003A5008876887 @default.
• W3201783003 hasAuthorship W3201783003A5011158103 @default.
• W3201783003 hasAuthorship W3201783003A5023146118 @default.
• W3201783003 hasAuthorship W3201783003A5035493599 @default.
• W3201783003 hasAuthorship W3201783003A5044240498 @default.
• W3201783003 hasAuthorship W3201783003A5054449581 @default.
• W3201783003 hasAuthorship W3201783003A5054474365 @default.
• W3201783003 hasAuthorship W3201783003A5064875263 @default.
• W3201783003 hasAuthorship W3201783003A5067699361 @default.
• W3201783003 hasAuthorship W3201783003A5075604584 @default.
• W3201783003 hasAuthorship W3201783003A5077564846 @default.
• W3201783003 hasAuthorship W3201783003A5085137623 @default.
• W3201783003 hasAuthorship W3201783003A5088980123 @default.
• W3201783003 hasBestOaLocation W32017830031 @default.
• W3201783003 hasConcept C126322002 @default.
• W3201783003 hasConcept C142724271 @default.
• W3201783003 hasConcept C159654299 @default.

• next